Alzheimer's Disease is the most common form of dementia and is a progressive condition that affects the brain, yet certain ...

Cassava Sciences' simufilam failed a Phase III trial for Alzheimer's disease, likely marking the end of a drug surrounded by ...

Italian researchers have developed a nasal spray showing promise in slowing Alzheimer's progression. Tests on mice with ...

Investigational simufilam failed to reduce cognitive or functional decline in Alzheimer's disease patients in the ReThink-ALZ ...

Cassava Sciences' Alzheimer's drug simufilam failed its Phase 3 trial and the stock plummet ~90%. See why I changed my rating ...

Cassava Sciences’ SAVA stock shed more than 80% of market value on Monday after the company reported that its lead pipeline ...

The International Working Group discussed diagnosing Alzheimer's disease among cognitively unimpaired individuals in a ...

Subtle signs of Alzheimer's disease can emerge decades before a diagnosis—often in the form of irregular behaviors that ...

Subtle signs of Alzheimer's disease can emerge decades before a diagnosis-;often in the form of irregular behaviors that reflect very early stages of brain dysfunction.

Tau behaves abnormally in the brain in people with Alzheimer’s disease. This latest study points to a reason why.

Could a computer detect the first subtle signs of Alzheimer’s disease long before doctors diagnose the patient? Scientists ...

In mice, inhibiting protein S-palmitoylation Counteracted accumulation of harmful proteins in neurons and delayed onset and progression of cognitive decline.